A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Parimifasor (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UPSTART
- Sponsors Lycera
- 03 Mar 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 14 Jun 2018 Status changed from active, no longer recruiting to completed.
- 26 Apr 2018 This trial has been completed in Poland (End date: 2018-03-26).